Table 1.

PD-1+ cell infiltrates in relation to clinical characteristics of the retrospective patient cohort (according to REMARK criteria)

Histologic subtypeNumber of tumorsNumber of tumors with PD-1+ cells present (%)aMean number of PD-1+ cells per core (when present)b
Serous (N = 206)75 (36.4)9.1
 DSS (y)—median (95% CI)
 Age (y)—median (range)
  Grade
   1110 (0)
   25618 (32.1)9.4
   313957 (41.0)9.0
  FIGO Stage
   I4815 (31.3)6.5
   II9038 (42.2)9.5
   III6822 (32.4)10.2
Mucinous (N = 30)0 (0)0
 DSS (y)—median (95% CI)
 Age (y)—median (range)
  Grade
   1110 (0)
   2170 (0)
   320 (0)
  FIGO stage
   I170 (0)
   II120 (0)
   III10 (0)
Endometrioid (N = 125)22 (17.6)7.4
 DSS (y)—median (95% CI)
 Age (y)—median (range)
  Grade
   18212 (14.6)4.6
   2357 (20.0)1.8
   383 (37.5)31.8
  FIGO stage
   I6919 (27.5)6.4
   II503 (6.0)14.1
   III60 (0)
Clear cell (N = 128)11 (8.6)6.1
 DSS (y)—median (95% CI)
 Age (y)—median (range)
  Grade
   1
   2
   312811 (8.6)6.1
  FIGO Stage
   I665 (7.6)4.8
   II546 (11.1)7.1
   III80 (0)
  • aTumors with a mean of ≥1 PD-1 positive cells per 0.6 mm core (2 duplicate cores, counted by two investigators).

  • bMean number of PD-1 positive cells per core in those tumors scored as positive in previous column.